Home
Products
Learn
About
Pricing
Log In

What are you looking for?

Home
Pricing
Compare AU

Compare WXOZ vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

SPDR S&P World Ex Australia Carbon Aware ETF

ASX

Buy

Buy

Global X S&P Biotech ETF

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the SPDR S&P World Ex Australia Carbon Aware ETF (WXOZ) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

WXOZ

CURE

Popularity

Low

Low

Pearlers invested

11

78

Median incremental investment

$993.75

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$1,252.80

$1,274.70

Average age group

> 35

> 35


Key Summary

WXOZ

CURE

Strategy

WXOZ.AX was created on 2013-03-18 by SPDR. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 411.75m in AUM and 784 holdings. The SPDR S&P World ex Australia Carbon Aware ETF seeks to closely track, before fees and expenses, the returns of the S&P Developed Ex-Australia LargeMidCap Carbon Aware Index.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Apple Inc (5.03 %)

Microsoft Corp (4.21 %)

NVIDIA Corp (3.45 %)

Natera Inc (2.70 %)

Vertex Pharmaceuticals Inc (2.67 %)

Alnylam Pharmaceuticals Inc (2.64 %)

Top 3 industries

Information Technology (57.51 %)

Communication Services (14.24 %)

Consumer Discretionary (6.87 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (66.13 %)

Japan (8.26 %)

United Kingdom of Great Britain and Northern Ireland (4.57 %)

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.07 %

0.45 %


Key Summary

WXOZ

CURE

Issuer

SPDR

Global X

Tracking index

S&P Developed ex Australia LargeMidCap AUD Index - AUD

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.07 %

0.45 %

Price

$46.40

$42.49

Size

$416.010 million

$28.994 million

10Y return

80.97 %

N/A

Annual distribution yield (5Y)

5.73 %

4.24 %

Market

ASX

ASX

First listed date

19/03/2013

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

WXOZ

CURE

Popularity

Low

Low

Pearlers invested

11

78

Median incremental investment

$993.75

$640.11

Median investment frequency

Monthly

Monthly

Median total investment

$1,252.80

$1,274.70

Average age group

> 35

> 35


Pros and Cons

WXOZ

CURE

Pros

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

  • Higher exposure to US market

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

WXOZ

CURE

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Higher distribution yield

Lower distribution yield